Trials / Completed
CompletedNCT01567813
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
Post-Licensure Observational Study of the Safety of GARDASIL™ in Males
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 114,035 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 9 Years – 26 Years
- Healthy volunteers
- Accepted
Summary
This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.
Conditions
Timeline
- Start date
- 2011-06-23
- Primary completion
- 2019-06-01
- Completion
- 2019-06-01
- First posted
- 2012-03-30
- Last updated
- 2022-07-22
Source: ClinicalTrials.gov record NCT01567813. Inclusion in this directory is not an endorsement.